Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
GlaxoSmithKline Pharmaceuticals Limited (500660) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of GlaxoSmithKline Pharmaceuticals Limited ₹1,472, price ₹2,775, upside -46.9%, quality 81 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
GP
Broad data
Sep 24, 2026
GlaxoSmithKline Pharmaceuticals Limited
500660 · BSEQuality Too ExpensiveExcellent quality, but the valuation looks stretched.
!Fair value ₹1,472 · Strongly overvalued (−46.9%)
✓Quality 81/100
✓Healthy Growth (revenue 5y +5.4 %/yr)
✓Highly profitable · 27.2% net margin (FY2025)
✓Low debt · generates free cash flow
✓Wide moat 78/100
Watch GlaxoSmithKline Pharmaceuticals Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹1,138 – ₹3,370 · fair‑value band ₹1,047 – ₹1,985 · the ₹2,775 price screens above the ₹1,472 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Company profile
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, manufactures, and distributes pharmaceutical products and vaccines worldwide. It offers prescription and non-prescription drugs for asthma, infectious diseases, mental health, digestive conditions, and other diseases; and vaccines for various therapeutic areas, primarily cancer.
Show more
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, manufactures, and distributes pharmaceutical products and vaccines worldwide. It offers prescription and non-prescription drugs for asthma, infectious diseases, mental health, digestive conditions, and other diseases; and vaccines for various therapeutic areas, primarily cancer. The company also provides medicinal substances, such as antibiotics, endocrine products, and basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, and its salts and esters; glycosides and vegetable alkaloids; and chemically pure sugar. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was founded in 1924 and is headquartered in Mumbai, India.
Stock analysis
GlaxoSmithKline Pharmaceuticals Limited (500660) currently trades at ₹2,775, while our model-based Fair Value estimate is ₹1,472, 46.9% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹2,022 per share, and 0 of the 23 models we run sit above the ₹2,775 price.
Bear case: the Asset-Based group reads lowest at ₹169.91, and 23 of the 23 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹1,047 (bear) to ₹1,985 (bull), the price of ₹2,775 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 81/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
GlaxoSmithKline Pharmaceuticals Limited reported revenue of ₹38.1B in FY2025 versus ₹32.8B in FY2021, a compound +3.8%/yr. Reported net income was ₹10.4B in FY2025, compounding −11.6%/yr from FY2021.
Key figures
Market cap ₹470B (≈ $4.9B) · P/E ratio 266.8 · P/S ratio 72.6 · EPS (TTM) ₹5.49 · Net margin 27.2% · Return on assets (EBIT) 22.4% · Free cash flow ₹8.5B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 58 out of 100 (medium confidence).
What moves the price
The share trades about 11% below its 52-week high and 32% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −40% fair-value upside, at −47%, 500660 screens richer than that median.
Fair Value models
Bear ₹1,047
Fair Value ₹1,472
Bull ₹1,985
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (₹4.15 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
₹1,075
₹1,451
₹1,956
81
Growth DCF
₹1,102
₹1,452
₹1,905
80
Owner Earnings
₹1,298
₹1,762
₹2,385
77
All 23 models by family
DCF Models
FCF DCF
₹1,075
₹1,451
₹1,956
81
Owner Earnings
₹1,298
₹1,762
₹2,385
77
5Y Revenue Exit
₹1,003
₹1,425
₹1,939
73
5Y EBITDA Exit
₹1,319
₹1,982
₹2,716
75
5Y P/E Exit
₹1,519
₹2,333
₹3,137
71
10Y Revenue Exit
₹998.33
₹1,373
₹1,824
67
10Y EBITDA Exit
₹1,215
₹1,738
₹2,372
69
10Y P/E Exit
₹1,337
₹1,969
₹2,668
64
Earnings-Based
Graham-Dodd
₹787.93
₹1,727
₹2,200
66
PEG = 1.0
₹273.34
₹390.49
₹507.63
57
EPV
₹1,125
₹1,284
₹1,420
71
Multiples
P/E Multiple
₹1,912
₹2,549
₹3,186
63
P/S Multiple
₹1,118
₹1,491
₹1,863
58
P/B Multiple
₹855.91
₹1,141
₹1,427
55
EV/EBIT
₹1,902
₹2,495
₹3,088
66
EV/EBITDA
₹1,666
₹2,181
₹2,695
67
EV/Revenue
₹1,018
₹1,401
₹1,784
54
Asset-Based
NCAV (Graham)
₹126.80
₹169.91
₹253.60
54
Growth DCF
Growth DCF
₹1,102
₹1,452
₹1,905
80
Rev-Margin DCF
₹1,003
₹1,438
₹1,899
73
Economic Profit
Residual Income
₹588.24
₹697.10
₹1,128
74
ROIC Compounder
₹1,141
₹1,320
₹1,486
72
Growth Earnings
Growth-Adj P/E
₹1,415
₹2,022
₹2,628
67
Notify me when 500660 reaches fair value
Put 500660 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
81/100
Of which business quality 79 · Market factors (momentum, volatility) 63
Profitability
93
Margins and returns on capital today
Quality Growth
52
Are margins and returns improving?
Cashflow
74
Earnings quality: real cash, not paper profit
Fin. Strength
92
Balance sheet, leverage, solvency risk
Investment
69
Disciplined investing over empire-building
Low Volatility
78
Calm price path (market factor)
Momentum
60
Price trend over the last 3–12 months (market factor)
52W Momentum
52
Distance to the 52-week high (market factor)
Net Issuance
82
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
70/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+1.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
Start year 2020 (pandemic). Over 10 years: +3.0% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.0%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+19.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+19.3%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.23.7% vs 11.9%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 33%
2025 sits 70% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+35.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +30.0% a year for the price.
500660 screens overvalued: fair value 47% below the price. Compare with Caregen Co →
Compare GlaxoSmithKline Pharmaceuticals Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 51 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Caregen Co 214370 | 40,850 KRW | 5,414 KRW | −87% |
| ST Pharm Co 237690 | 91,700 KRW | 50,110 KRW | −45% |
| Oscotec Inc 039200 | 35,650 KRW | 21,262 KRW | −40% |
| DongKook Pharmaceutical Co 086450 | 22,150 KRW | 28,372 KRW | +28% |
| SHUKRAPHAR SHUKRAPHAR | ₹55.87 | ₹9.09 | −84% |
| Huons Global Co 084110 | 22,950 KRW | 46,562 KRW | +103% |
| BINEX Co 053030 | 6,490 KRW | 1,844 KRW | −72% |
| Kolon Life Science Inc 102940 | 14,800 KRW | 37,129 KRW | +151% |
| VIKRAMTH VIKRAMTH | ₹405.90 | ₹444.16 | +9% |
| JW Shinyak Corporation 067290 | 2,990 KRW | 1,326 KRW | −56% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is GlaxoSmithKline Pharmaceuticals Limited (500660) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹1,472 versus a price of ₹2,775, about −47% upside (overvalued).
What is the fair value of 500660?
Our model-based fair value for GlaxoSmithKline Pharmaceuticals Limited is ₹1,472 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹2,775.
What is the quality score of 500660?
GlaxoSmithKline Pharmaceuticals Limited has a Quality Score of 81/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for GlaxoSmithKline Pharmaceuticals Limited (500660)?
Our model-based price target is the fair value of ₹1,472 (as of Sep 24, 2026) from 23 valuation models. Cautious scenario ₹1,047, optimistic scenario ₹1,985. It is a calculation from audited fundamentals, not an analyst target.
What is the GlaxoSmithKline Pharmaceuticals Limited stock forecast for 2026?
Our models put fair value at ₹1,472, about −47% upside versus a price of ₹2,775 (overvalued). Cautious scenario ₹1,047, optimistic scenario ₹1,985. The calculation is refreshed regularly with new filings.
What growth is priced into GlaxoSmithKline Pharmaceuticals Limited (500660)?
For today's price to be fair in a discounted-cash-flow model, GlaxoSmithKline Pharmaceuticals Limited would have to grow free cash flow by +35.4 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.4 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 500660 use?
Our models discount GlaxoSmithKline Pharmaceuticals Limited at 12.4 %: a base by market capitalisation (mid), country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For GlaxoSmithKline Pharmaceuticals Limited that is +35.4 % per year a year over ten years, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has GlaxoSmithKline Pharmaceuticals Limited (500660) delivered so far?
Over the past 5 years revenue at GlaxoSmithKline Pharmaceuticals Limited grew +5.4 % a year. The price currently implies +35.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of GlaxoSmithKline Pharmaceuticals Limited (500660) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into GlaxoSmithKline Pharmaceuticals Limited (+35.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of GlaxoSmithKline Pharmaceuticals Limited (500660)?
The free-cash-flow yield on the price is 1.80 %: that much free cash flow GlaxoSmithKline Pharmaceuticals Limited produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of GlaxoSmithKline Pharmaceuticals Limited (500660)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For GlaxoSmithKline Pharmaceuticals Limited it is ₹1,472 per share (as of Sep 24, 2026), against a price of ₹2,775. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is GlaxoSmithKline Pharmaceuticals Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 500660 trades above its calculated fair value: price ₹2,775, fair value ₹1,472, a gap of about −47% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 500660?
No. The price is what the market pays today (₹2,775); the fair value is what the company's own numbers justify (₹1,472). For GlaxoSmithKline Pharmaceuticals Limited the two are ₹1,302 per share apart. That gap is exactly why we show both numbers side by side.
How much is GlaxoSmithKline Pharmaceuticals Limited worth?
The market values GlaxoSmithKline Pharmaceuticals Limited at about ₹470B (market capitalisation, as of Sep 24, 2026). Per share that is ₹2,775; our models calculate a fair value of ₹1,472 per share.
What do the bullish and bearish scenarios say about 500660?
Our models span a range for GlaxoSmithKline Pharmaceuticals Limited: cautious scenario ₹1,047, base ₹1,472, optimistic ₹1,985 per share (as of Sep 24, 2026, price ₹2,775). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 500660?
GlaxoSmithKline Pharmaceuticals Limited trades at a price-to-earnings ratio of 266.8 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹1,472 is built from several models across several years. Other multiples: P/B 0.1.
How far is 500660 from its 52-week high?
GlaxoSmithKline Pharmaceuticals Limited trades at ₹2,775, about 11% below its 52-week high of ₹3,106 and 32% above the low of ₹2,103 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹1,472 is for.
Which stocks are comparable to GlaxoSmithKline Pharmaceuticals Limited?
From the same area (Healthcare) we also value Caregen Co, ST Pharm Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is GlaxoSmithKline Pharmaceuticals Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹2,775, calculated fair value ₹1,472 (−47%), Quality Score 81/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 500660 calculated?
We run GlaxoSmithKline Pharmaceuticals Limited through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹1,472, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. GlaxoSmithKline Pharmaceuticals Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of GlaxoSmithKline Pharmaceuticals Limited (500660)?
The closing price on Oct 1, 2026 was ₹2,775. Our model-based fair value is ₹1,472, about −47% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with GlaxoSmithKline Pharmaceuticals Limited right now?
A high-quality business (quality 81/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (₹1,985). The favourable scenario is already priced in. A fairly wide model range (₹1,047 to ₹1,985) leaves room in how you read the outcome.
Key figures of GlaxoSmithKline Pharmaceuticals Limited
How large is the market capitalisation of GlaxoSmithKline Pharmaceuticals Limited (500660)?
The market capitalisation of GlaxoSmithKline Pharmaceuticals Limited is ₹470B (≈ $4.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of GlaxoSmithKline Pharmaceuticals Limited (500660)?
The price-to-sales ratio of GlaxoSmithKline Pharmaceuticals Limited is 72.6 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of GlaxoSmithKline Pharmaceuticals Limited (500660)?
Earnings per share at GlaxoSmithKline Pharmaceuticals Limited are ₹5.49 (price ÷ EPS = P/E 266.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of GlaxoSmithKline Pharmaceuticals Limited (500660)?
The net margin of GlaxoSmithKline Pharmaceuticals Limited is 27.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of GlaxoSmithKline Pharmaceuticals Limited (500660)?
On an EBIT basis the return on assets of GlaxoSmithKline Pharmaceuticals Limited is 22.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
Free · no account needed
Watch GlaxoSmithKline Pharmaceuticals Limited in the live analysis
One click puts GlaxoSmithKline Pharmaceuticals Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.